このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Non-invasive Brain Stimulation and Cognitive Processing in Depression

2018年5月3日 更新者:University College, London

Neural, Cognitive, and Clinical Effects of Prefrontal Cortex Stimulation to Enhance Psychotherapy in Depression: a Double-blind Randomized Controlled Trial

Depression is a serious mental health problem that affects millions. Depression is usually treated using drugs and/or psychotherapy, but neither approach is successful for everyone, and some people do not respond to either. Therefore it is crucial that we continue to seek new methods for treating depression, and develop enhancements to existing treatments. In recent years, trials have documented improvements in depressive symptoms using noninvasive brain stimulation techniques, such as transcranial direct current stimulation, or tDCS. Our aim in this research is to investigate the effects of brain stimulation combined with psychological therapy in depression, an area that remains largely unexplored. Specifically, stimulation of the dorsolateral prefrontal cortex (DLPFC), a brain region known to work inefficiently in depression, has been shown to result in an improvement of depressive symptoms, as well as in the patient's 'cognitive control' abilities. Because 'cognitive control' processes, such as concentrating and ignoring distracting thoughts, are engaged during psychological therapies for depression, we predict that DLPFC stimulation should improve how patients respond to psychological therapy. This study has considerable implications as it will potentially benefit a large number of patients for which current treatments are ineffective.

調査の概要

詳細な説明

We propose to investigate the effect of applying transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (LDLPFC) immediately prior to each of 8 sessions of cognitive behavioural therapy (CBT), a type of psychological therapy. In addition we will investigate whether tDCS effects on CBT are due to changes in cognitive control using both behavioural and neuroimaging measures.

We hypothesize that tDCS, thanks to its enduring effects, should improve the benefits of CBT, through the enhancement of cognitive control in the patient.

Null hypothesis: mood and cognitive performance will be equivalent in depressed individuals who undergo tDCS and those who undergo sham stimulation.

Experimental hypothesis: mood and cognitive performance will be improved in depressed individuals who undergo tDCS relative to those who undergo sham stimulation.

Sixty patients suffering from depression will be recruited, and a double-blind, sham-controlled, randomised design will be used. This design means that neither participants nor researchers are aware of the conditions they have been assigned to, and has been chosen to eliminate participant expectancy ("placebo") effects and researcher bias. To ensure that 30 participants are included in each group, we will use a balanced assignment algorithm at entry into the study, which will maximise statistical power. Since the results of a study of this type have never previously been reported (to our knowledge), clinical equipoise exists, mandating the use of a sham stimulation arm. Patients with depression will be randomly assigned to one of two groups: tDCS or sham stimulation. To ensure that 30 participants are included in each group, we will use a balanced assignment algorithm at entry into the study. The whole study will be spread over 16 weeks for each participant with the following time course:

  • start: baseline MRI brain scan while completing a cognitive control task; measures of depressive symptoms
  • weeks 1 to 8: one session per week of tDCS or sham stimulation (20 min, while completing a cognitive control task) immediately followed by CBT (1 hour); measures of depressive symptoms
  • end of week 8: post-treatment MRI scan while completing a cognitive control task and measures of depressive symptoms
  • week 9 to 16: up to one session per week of CBT as usual (1 hour) without stimulation
  • end of week 16, or end of CBT (whichever is sooner): measures of depressive symptoms

MRI scans will have two purposes, (1) localising the area of the DLPFC for stimulation, and (2) comparing brain responses to a cognitive control task before and after treatment.

The tDCS will be delivered using neuroConn stimulators. A 1 milliamp (mA) current will be delivered for 20 minutes through damp sponges soaked in saline solution and attached to the head of the patient using a cap. One electrode will be placed on the forehead over the LDLPFC, and the other on the left shoulder blade or left cheek to record baseline electrical signal. In the sham condition, there will be a brief current change at the beginning and end of each stimulation session, in order to mimic the effect of an actual stimulation, but no current will be delivered in between.

CBT sessions will be delivered weekly, immediately after the tDCS or sham stimulation for the first 8 weeks, and provided by qualified psychological therapists as part of standard National Health Services (NHS) care.

Mood will be assessed before the start of the study (first MRI scan), each week for the 8 week stimulation phase, at the second MRI scan and after 16 weeks, using the Montgomery and Asberg Depression Rating Scale (MADRS).

Patients will perform a task to assess their cognitive control abilities during the MRI scans, as well as during each of the 8 stimulation sessions. During this task, visual stimuli will be presented to the subject, who will have to make different responses to these stimuli by pressing buttons on a response box.

研究の種類

介入

入学 (実際)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • London、イギリス、WC1N 3AR
        • UCL Institute of Cognitive Neuroscience

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients suffering from unipolar major depressive disorder
  • First depressive episode onset before 40 years old
  • Right-handedness
  • English as first language
  • Intention to commence a course of cognitive behavioural therapy

Exclusion Criteria:

  • Antidepressant or other psychotropic medication at any time during the study or within previous 4 weeks (8 for fluoxetine)
  • Recent illicit drug use
  • Prior mixed, manic, or psychotic symptoms or other psychiatric or neurological illness
  • Standard exclusion criteria for MRI scanning: pregnancy, breast feeding, any immovable metal in the body, weight above 250 lbs, claustrophobia
  • tDCS safety criteria: skin disease or skin treatment that could potentially cause irritation with electrical stimulation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Patients tDCS
A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.

Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.

Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between.

他の名前:
  • NeuroConn DC-STIMULATOR PLUS, number 0061.
8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
偽コンパレータ:Patients - Sham
Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Beck Depression Inventory (BDI) score
時間枠:Change from Baseline BDI score at 8 sessions
BDI scores will constitute a self-report measure of depression symptoms over the course of the trial.
Change from Baseline BDI score at 8 sessions
Beck Depression Inventory (BDI) score
時間枠:Change from Baseline BDI score at 16 sessions or when the patient ceases CBT, whichever came first
BDI scores will constitute a self-report measure of depression.
Change from Baseline BDI score at 16 sessions or when the patient ceases CBT, whichever came first
Hamilton Depression Rating Scale (HAMD)
時間枠:Change from Baseline HAMD at 8 CBT sessions
HAMD scores will constitute an interview scale from baseline to end of tDCS.
Change from Baseline HAMD at 8 CBT sessions

二次結果の測定

結果測定
メジャーの説明
時間枠
Cognitive Control Performance
時間枠:Week 0 (Baseline), 1, 2, 3, 4, 5, 6, 7, 8, and 9
Evolution of behavioral performance on the cognitive control task over the course of the trial, performed inside the scanner at baseline and after session 8, and during tDCS stimulation once a week for 8 weeks.
Week 0 (Baseline), 1, 2, 3, 4, 5, 6, 7, 8, and 9
Functional Magnetic Resonance Imaging (fMRI) data
時間枠:Change from Baseline brain responses to the cognitive control task at week 9
Brain responses to the cognitive control task in the LDLPFC and other relevant brain region will be analysed and compared after relative to before treatment.
Change from Baseline brain responses to the cognitive control task at week 9

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Stephen Pilling, PhD、University College, London
  • 主任研究者:Jonathan P Roiser, PhD、University College, London

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2014年7月22日

一次修了 (実際)

2017年3月7日

研究の完了 (実際)

2017年9月20日

試験登録日

最初に提出

2013年6月5日

QC基準を満たした最初の提出物

2013年6月7日

最初の投稿 (見積もり)

2013年6月11日

学習記録の更新

投稿された最後の更新 (実際)

2018年5月9日

QC基準を満たした最後の更新が送信されました

2018年5月3日

最終確認日

2018年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 13/0256

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する